Japanese markets end on a flat note

Explore Business Standard
Associate Sponsors

Eisai shares soared 7.4 percent as the failure of Novo Nordisk's semaglutide to reduce Alzheimer's disease progression removed a "modest" or "perceived" overhang on Biogen, which developed and co-markets Leqembi with partner Eisai.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
First Published: Nov 25 2025 | 5:06 PM IST